louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04888065: Understand the Association Between Peritoneal Dialysis Status and Gene Polymorphisms of VEGF and KDR
Official title: Gene Polymorphisms of VEGF and KDR Are Associated With Initial High Transport Status in Peritoneal Dialysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Peritoneal Dialysis
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2021-05-17
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Both gender, end stage renal disease on PD treatment

Brief summary: Peritoneal dialysis (PD) is an effective and successful way of renal replacement therapy. The initial transport status is related to distribution of blood vessels and micro inflammation state in peritoneum before PD. Vascular endothelial growth factor(VEGF) and its receptor, kinase insert domain containing receptor(KDR) may play important roles on initial transport status.

This study include 200 PD patients from Renji Hospital in Shanghai, China. According to the 4h D/P Cr within three months of starting PD therapy, we analyzed the association between the polymorphisms of VEGF and KDR and initial peritoneal transport property.


Eligibility criteria: Inclusion Criteria:

1. Patients are Han Chinese;
2. Patients prepare for dialysis in our center, and start PD within 3 months after abdominal catheterization;
3. Patients successfully complete the first peritoneal equilibration test(PET);
4. Follow up regularly in our PD center.

Exclusion Criteria:

1. Patients from hemodialysis to peritoneal dialysis;
2. Patients who need peritoneal dialysis due to transplant-renal loss;

Primary outcomes:
measure: The relationship between VEGF and KDR Gene polymorphisms and initial transport status in peritoneal dialysis
timeFrame: For each patient, the outcome would be cross sectional measured at the time the patient does first/initial Peritoneal Equilibration Test. The data collection time period of the study is within 3 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Renji Hospital
state: Shanghai
Study officials:
affiliation: RenJi Hospital
name: YUE QIAN, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Qian Y, Ding L, Cao L, Yu Z, Shao X, Wang L, Zhang M, Wang Q, Che X, Jiang N, Yan H, Fang W, Jin Y, Huang J, Gu A, Ni Z. Gene polymorphisms of VEGF and KDR are associated with initial fast peritoneal solute transfer rate in peritoneal dialysis. BMC Nephrol. 2022 Nov 14;23(1):365. doi: 10.1186/s12882-022-02975-5.
Clinical trial NCT04387266: To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
Official title: A Retrospective Real-world Study in Patients With Nasopharyngeal Carcinoma: to Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Nasopharyngeal Carcinoma
Lead sponsor: Fujian Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2020-05-13
Enrollment: 471
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Non-metastatic NPC patients treated with modified reduce-volume target IMRT in our institution

Brief summary: This is a retrospective real-world study to evaluate the efficacy and feasibility of modified reduce-volume target IMRT in the treatment of patients with non-metastatic NPC


Eligibility criteria: Inclusion Criteria:

1. Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma;
2. Newly diagnosed, non-metastatic and treated with modified reduce-volume IMRT;
3. Patients with baseline MRI date of nasopharynx and neck, and completed the first course of treatment in our hospital;
4. Diagnosis time: November 1, 2014 to December 31 , 2017

Exclusion Criteria:

1. Disease progression during IMRT;
2. Previous malignancy or other concomitant malignant diseases;
3. The evaluation information of tumor efficacy can not be obtained;
4. Receive blind treatment in other clinical research.

Primary outcomes:
measure: Local failure-free survival (LFFS)
timeFrame: 60 month
Secondary outcomes:
Other outcomes:
Locations:
city: Fuzhou
country: China
facility: Department of radiation oncology, Fujian cancer hospital
state: Fujian
Study officials:
References:
Clinical trial NCT05936866: Effects of Antenatal Exercises on Maternal Birth Outcomes
Official title: Effect of Antenatal Pelvic Floor Stretching Vs Strengthening Exercises on Maternal Birth Outcomes in Primigravida
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pregnancy Related
Keywords: Pregnancy Related
Pelvic Floor Muscle Weakness
Delivery Delayed
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-07-10
Enrollment: 42
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study is aimed to determine the effects of pelvic floor stretching Vs strengthening on maternal birth outcomes and postpartum urogenital distress in primigravida.

Detailed description: The effects of pelvic floor muscle exercises on the symptoms of postpartum urinary distress is not known, so there is a need to determine whether strengthening or stretching of pelvic floor muscles help in reducing the risk of developing urogenital distress in postpartum period of females. The positive effect of pelvic floor muscle training on duration of labor and maternal birth outcomes is understood. As stated in a systemic review of pelvic floor interventions during pregnancy. The researches done on effect of pelvic floor muscle exercises, included once a week supervised session of sustained pelvic floor muscle contractions with rest intervals and fast contractions with respective rest intervals along with daily home sessions of the same exercises.

Eligibility criteria: Inclusion Criteria:

* Primigravida

Exclusion Criteria:

* Any Contraindications to performing an exercise during pregnancy based on recommendations of the American College of Obstetricians and Gynecologists (ACOG)
* females opting for Elective C section

Primary outcomes:
measure: Mode of delivery
timeFrame: 13th Week
measure: Duration of labour
timeFrame: 13th Week
measure: Number of vaginal inductions
timeFrame: 13th Week
Secondary outcomes:
measure: Urogenital Distress Inventory
timeFrame: 15th Week
Other outcomes:
Locations:
city: Abbottabad
country: Pakistan
facility: Doctors hospital
state: KPK
Study officials:
affiliation: Riphah International University
name: Sarah Ehsan, PP-DPT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05730166: Pain Inhibitory Effects of Other Pain Induced by Mechanical Pressure at Different Intensities
Official title: Conditioned Pain Modulation Induced by Mechanical Stimulation. A Mechanism of Manual Therapy Analgesia: Study 2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Conditioned Pain Modulation
Manual Therapy
Physiotherapy
Physical therapy
Lead sponsor: Universidad Rey Juan Carlos
Sponsor class: OTHER
First posted: 2023-02-15
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective is to estimate the effects on pain thresholds of a painful mechanical stimulus on the upper trapezius at moderate intensity compared to mild intensity or non-painful.

Detailed description: The mechanical stimulus produced in manual therapy (MT) techniques elicits neurophysiological responses within the peripheral and central nervous system responsible for pain inhibition. Almost all types of MT elicit a neurophysiological response that is associated with the descending pain modulation circuit. But it has not been demonstrated whether this inhibition occurs through a conditioned pain modulation mechanism induced by painful mechanical stimulation that is carried out with manual therapy techniques.

Eligibility criteria: Inclusion Criteria:

* healthy male or female between 18 and 65 years
* Free of pain and with no history of chronic pain

Exclusion Criteria:

* Pregnant or having given birth within the last year

Primary outcomes:
measure: Change from Baseline in Tibialis Anterior Pressure Pain Threshold (PPT) to immediate post-conditioning stimulus
timeFrame: At baseline and immediately after the conditioning stimulus
Secondary outcomes:
Other outcomes:
Locations:
city: Alcorcón
country: Spain
facility: Universidad Rey Juan Carlos
state: Madrid
Study officials:
affiliation: Universidad Rey Juan Carlos
name: Josué Fernández Carnero, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06345066: A Study of LY3841136 in Overweight and Obese Participants
Official title: A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese Participants
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Obesity
Overweight
Keywords: Safety
Tolerability
Body weight
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2024-04-03
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.


Eligibility criteria: Inclusion Criteria:

* Male and female participants who are overtly healthy as determined by medical evaluation
* Have a stable body weight and Body Mass Index in range of 27 to 45 kilogram per meter square (kg/m²).
* Have clinical laboratory test results within normal reference range
* Have venous access sufficient to allow for blood sampling
* Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

Exclusion Criteria:

* Have type 1 or type 2 diabetes mellitus
* Have an abnormal 12-lead electrocardiogram (ECG)
* Have a history or presence of psychiatric disorders
* Have abnormal blood pressure and pulse rate
* Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product.

Primary outcomes:
measure: Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration
timeFrame: Baseline up to 42 weeks
Secondary outcomes:
measure: Percent change from baseline in body weight
timeFrame: Baseline, Week 42
measure: Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY3841136
timeFrame: Predose up to 42 weeks
measure: Pharmacokinetics (PK): Maximum plasma concentration (Cmax) of LY3841136
timeFrame: Predose up to 42 weeks
Other outcomes:
Locations:
city: Daytona Beach
country: United States
facility: Fortrea Clinical Research Unit
state: Florida
city: Dallas
country: United States
facility: Fortrea Clinical Research Unit
state: Texas
city: Madison
country: United States
facility: Fortrea Clinical Research Unit
state: Wisconsin
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT04294966: Age-Related Effects of THC
Official title: Age-Related Effects of THC
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Tolerance
Adolescent Behavior
THC
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2020-03-04
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Increased accessibility to cannabis and its primary psychoactive constituent THC has raised public health concerns. One major concern surrounds the potential risks associated with acute THC intoxication and who might be most at risk. A second major concern is the need to develop sensitive measures that can detect THC intoxication after recent use and enable robust comparisons of intoxication to determine sources of risk. One potential source of risk is age, specifically during the period of adolescence.

Detailed description: There is limited knowledge on the effects of THC in adolescents vs adults. One recent report compared responses to vaporized cannabis in heavy adolescent vs adult cannabis users and found that the adolescents were less sensitive to the drug on most measures. However, their findings were complicated by several factors: i) the study used vaporized cannabis, which may have other constituents and does not offer full control of the dose, ii) the participants were heavy users, making it difficult to determine the influence of prior drug exposure, and iii) the participants were not drug-free at the time of testing. Prior exposure to THC can lead to tolerance, and adolescents and adults may differ in the rate at which they develop tolerance, consistent with changes in CB1R receptor function. Our study will compare adolescent (here, aged 18 to 20) and adult (here, aged 30 to 40) responses to THC in relatively light cannabis users who are drug-free at the time of testing.

Eligibility criteria: Inclusion Criteria:

* 18-20 years old OR 30-40 years old
* Body Mass Index 19-26
* High school education, fluent in English
* Occasional cannabis users ( 0 times in past 30 days AND used cannabis no more than 20 times in lifetime)

Exclusion Criteria:

* History of daily cannabis use
* Past or present severe substance use disorder
* Current or past diagnosis with drug treatment for psychosis/bipolar/schizophrenia
* Cardiovascular illness, high blood pressure, abnormal electrocardiogram
* Current medications
* Pregnant or planning to become pregnant

Primary outcomes:
measure: Change From Baseline in Profile of Mood States (POMS)
timeFrame: Through Study Completion, an average of 3 weeks (Baseline - time 0 to Time point 9 (Study Completion))
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago Hospital
state: Illinois
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
Study officials:
References:
Clinical trial NCT06391866: Neuroinflammation/Oxidative Stress/Cardiac Surgery
Official title: Assessing Neuroinflammation and Oxidative Stress After Cardiac Surgery: Unveiling Molecular Dynamics and Clinical Outcomes
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neuroinflammation
Lead sponsor: Europainclinics z.ú.
Sponsor class: OTHER
Collaborators: name: East Slovak Institute for Cardiovascular Diseases
First posted: 2024-04-30
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient undergoing cardiac surgery

Brief summary: The prospective observational study delves into the complex relationship between neuroinflammation and oxidative stress in post-cardiac surgery complications, focusing on postoperative cognitive dysfunction.

Detailed description: The prospective observational study meticulously examines the interplay between neuroinflammation and oxidative stress in the realm of post-cardiac surgery complications, specifically targeting postoperative cognitive dysfunction. Its primary objective is to comprehensively assess the sustained influence of these intricate processes on cognitive function and overall well-being, extending beyond the immediate aftermath of surgery. The research endeavors to probe deeply into the molecular mechanisms and clinical ramifications associated with neuroinflammation and oxidative stress, centering on their pivotal role in shaping the onset and trajectory of postoperative cognitive dysfunction.

Eligibility criteria: Inclusion Criteria:

* Undergoing cardiosurgical operation
* Absence of previous neurological disease
* Signed informed consent document

Exclusion Criteria:

* Presence of neoplasms
* Neurological Disease
* Refusal to participate in the clinical trial

Primary outcomes:
measure: Number and type of early complications after surgery
timeFrame: 1 month
measure: Number and type of postoperative complications
timeFrame: 6 months
Secondary outcomes:
measure: Estimating biochemical parameters
timeFrame: 1 hour
measure: Estimating biochemical parameters
timeFrame: 6 hours
measure: Estimating biochemical parameters Third biochemical examination
timeFrame: 1 hour
measure: Estimating biochemical parameters
timeFrame: 6 hours
Other outcomes:
Locations:
city: Košice
country: Slovakia
facility: Europainclinics
Study officials:
References:
Clinical trial NCT00890266: Corneal Collagen Cross-linking With Hypotonic Riboflavin in Corneas Thinner Than 400 Microns
Official title: Collagen Cross-linking With Riboflavin in a Hypotonic Solution, With UV Light, on Corneas Less Than 400 Microns Thick: an Exploratory Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Keratoconus
Keywords: keratoconus
collagen cross-linking
riboflavin
UV light
Lead sponsor: Moorfields Eye Hospital NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: Peschke Meditrade, GmbH
First posted: 2009-04-29
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Corneal ectasia is a relative weakness in the structure of the cornea, which produces a progressive change in its shape which results in visual distortion. It is known that collagen cross-linking in the cornea occurs naturally with age, and in diabetes, both of which seem to prevent progressive ectasia. Corneal collagen cross-linking with riboflavin on corneas thicker than 400 microns has been shown to stabilize the cornea in keratoconus, and prevent progression of the disease.

The purpose of this study is to determine whether corneal collagen cross-linking with riboflavin in a hypotonic solution, with UV light, on corneas less than 400 microns thick, leads to stabilisation of corneal ectasia.

Detailed description: When cross-linking corneas of \> 400 microns, riboflavin in a solution with high molecular weight dextran T500 is used to prevent corneal swelling during the administration of the drops and the UV treatment. However if riboflavin is applied to a cornea in a hypotonic solution (saline), then transient corneal oedema is created with thickening of the corneal stroma. In this way it is thought that the temporarily thickened cornea can be treated with UV whilst still providing a sufficient thickness to absorb the UV to an extent that endothelial cell damage is avoided.

Eligibility criteria: Inclusion Criteria:

* Keratoconus
* Corneas thinner than 400 microns, but thicker than 250 microns

Exclusion Criteria:

* Evidence of other corneal disease in the eye to be treated (e.g., Herpes simplex keratitis)
* Women who are pregnant or nursing at the time of the initial treatment

Primary outcomes:
measure: Change in keratometry/corneal topography
timeFrame: 3 months
Secondary outcomes:
measure: Corneal endothelial cell count
timeFrame: 3 months
measure: Visual acuity
timeFrame: 3 months
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Moorfields Eye Department at St George's Hospital
state: Greater London
Study officials:
affiliation: Moorfields Eye Hospital NHS Foundation Trust
name: Chad K Rostron, FRCOphth
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hafezi F, Mrochen M, Iseli HP, Seiler T. Collagen crosslinking with ultraviolet-A and hypoosmolar riboflavin solution in thin corneas. J Cataract Refract Surg. 2009 Apr;35(4):621-4. doi: 10.1016/j.jcrs.2008.10.060.
Clinical trial NCT03742466: Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients
Official title: Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients. A Single-blind Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Carpal Tunnel Syndrome
Chronic Pain
Scleroderma
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-11-15
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Carpal tunnel syndrome is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent local ozone therapy could offer symptom improvement in scleroderma patients with Carpal tunnel syndrome

Detailed description: Carpal tunnel syndrome (CTS) is the most common compression syndrome the upper extremities. Its problem has a high prevalence ranged estimated prevalence of 3.8% in the general population, 3 and 7.8% in the working population. It occurs at any age, especially in individuals in their 40s to 60s, and the male: female ratio is reported to be 3:7. A lot of treatment modalities have been tried to improve the condition, starting from local anesthetic injection, steroid, and up to surgical decompression of the nerves.

Scleroderma patients are a special group which usually sufferers from such problem

Eligibility criteria: Inclusion Criteria:

* adult patients with scleroderma
* complaining of carpal tunnel syndrome of 3-month duration or more
* diagnosed axonal neuropathy using electrodiagnosis, nerve conduction study

Exclusion Criteria:

* patient refusal
* infection at the site of intervention
* previous injection in the recent 3 months
* Coagulopathy

Primary outcomes:
measure: to assess pain alleviation through the visual analog scale (VAS)
timeFrame: 6 months
Secondary outcomes:
measure: Changes in median nerve conduction parameters
timeFrame: 6 months
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Emad Zarief Kamel Said
Study officials:
References: